title: Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies
abstract: OBJECTIVE: The primary objective of these Phase I/II dose-escalation studies is to evaluate the safety of boronophenylalanine (BPA)-fructose-mediated boron neutron capture therapy (BNCT) for patients with glioblastoma multiforme (GBM). A secondary purpose is to assess the palliation of GBM by BNCT, if possible. METHODS: Thirty-eight patients with GBM have been treated. Subtotal or gross total resection of GBM was performed for 38 patients (median age, 56 yr) before BNCT. BPA-fructose (250 or 290 mg BPA/kg body weight) was infused intravenously, in 2 hours, approximately 3 to 5 weeks after surgery. Neutron irradiation was begun between 34 and 82 minutes after the end of the BPA infusion and lasted 38 to 65 minutes. RESULTS: Toxicity related to BPA-fructose was not observed. The maximal radiation dose to normal brain varied from 8.9 to 14.8 Gy-Eq. The volume-weighted average radiation dose to normal brain tissues ranged from 1.9 to 6.0 Gy-Eq. No BNCT-related Grade 3 or 4 toxicity was observed, although milder toxicities were seen. Twenty-five of 37 assessable patients are dead, all as a result of progressive GBM. No radiation-induced damage to normal brain tissue was observed in postmortem examinations of seven brains. The minimal tumor volume doses ranged from 18 to 55 Gy-Eq. The median time to tumor progression and the median survival time from diagnosis (from Kaplan-Meier curves) were 31.6 weeks and 13.0 months, respectively. CONCLUSION: The BNCT procedure used has been safe for all patients treated to date. Our limited clinical evaluation suggests that the palliation offered by a single session of BNCT is comparable to that provided by fractionated photon therapy. Additional studies with further escalation of radiation doses are in progress.
authors.affiliation: Medical Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA.
authors.initials: AD
authors.lastname: Chanana
authors.initials: J
authors.lastname: Capala
authors.initials: M
authors.lastname: Chadha
authors.initials: JA
authors.lastname: Coderre
authors.initials: AZ
authors.lastname: Diaz
authors.initials: EH
authors.lastname: Elowitz
authors.initials: J
authors.lastname: Iwai
authors.initials: DD
authors.lastname: Joel
authors.initials: HB
authors.lastname: Liu
authors.initials: R
authors.lastname: Ma
authors.initials: N
authors.lastname: Pendzick
authors.initials: NS
authors.lastname: Peress
authors.initials: MS
authors.lastname: Shady
authors.initials: DN
authors.lastname: Slatkin
authors.initials: GW
authors.lastname: Tyson
authors.initials: L
authors.lastname: Wielopolski